CoChat

The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor

Open access
McLaughlin, Sara Koenig, Olsen, Sarah Naomi, Dake, Benjamin, De Raedt, Thomas, Lim, Elgene, Bronson, Roderick Terry, Beroukhim, Rameen, Polyak, Kornelia, Brown, Myles, Kuperwasser, Charlotte, Cichowski, Karen · 2013 · Cancer Cell
Cited by 135

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

SUMMARY RAS genes are commonly mutated in cancer; however, RAS mutations are rare in breast cancer, despite the fact that Ras and ERK are frequently hyperactivated. Here we report that the RasGAP gene, RASAL2, functions as a tumor and metastasis suppressor. RASAL2 is mutated or suppressed in human breast cancer and RASAL2 ablation promotes tumor growth, progression, and metastasis in mouse models. In human breast cancer RASAL2-loss is associated with metastatic disease, low RASAL2 levels correlate with recurrence of luminal B tumors, and RASAL2 ablation promotes metastasis of luminal mouse tumors. Additional data reveal a broader role for RASAL2 inactivation in other tumor-types. These studies highlight the expanding role of RasGAPs and reveal an alternative mechanism of activating Ras in cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2013.08.004

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 29

  1. Bamford, 2004, The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website, Br. J. Cancer, 91, 355, 10.1038/sj.bjc.6601894 · DOI · Paper page
  2. Bernards, 2003, GAPs galore! A survey of putative Ras superfamily GTPase activating proteins in man and Drosophila, Biochim. Biophys. Acta, 1603, 47
  3. 2012, Comprehensive molecular portraits of human breast tumours, Nature, 490, 61, 10.1038/nature11412 · DOI · Paper page
  4. Cawthon, 1990, A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations, Cell, 62, 193, 10.1016/0092-8674(90)90253-B · DOI · Paper page
  5. Dote, 2004, Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breast cancer, Clin. Cancer Res., 10, 2082, 10.1158/1078-0432.CCR-03-0236 · DOI
  6. Downward, 2003, Targeting RAS signalling pathways in cancer therapy, Nat. Rev. Cancer, 3, 11, 10.1038/nrc969 · DOI · Paper page
  7. Gewinner, 2009, Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling, Cancer Cell, 16, 115, 10.1016/j.ccr.2009.06.006 · DOI · Paper page
  8. Guy, 1992, Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease, Proc. Natl. Acad. Sci. USA, 89, 10578, 10.1073/pnas.89.22.10578 · DOI · Paper page
  9. Herschkowitz, 2007, Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors, Genome Biol., 8, R76, 10.1186/gb-2007-8-5-r76 · DOI · Paper page
  10. Hollestelle, 2007, Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines, Mol. Cancer Res., 5, 195, 10.1158/1541-7786.MCR-06-0263 · DOI · Paper page
  11. Hölzel, 2010, NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome, Cell, 142, 218, 10.1016/j.cell.2010.06.004 · DOI · Paper page
  12. Hu, 2006, The molecular portraits of breast tumors are conserved across microarray platforms, BMC Genomics, 7, 96, 10.1186/1471-2164-7-96 · DOI · Paper page
  13. Hu, 2008, Regulation of in situ to invasive breast carcinoma transition, Cancer Cell, 13, 394, 10.1016/j.ccr.2008.03.007 · DOI · Paper page
  14. Jézéquel, 2012, bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer, Breast Cancer Res. Treat., 131, 765, 10.1007/s10549-011-1457-7 · DOI · Paper page
  15. Johannessen, 2005, The NF1 tumor suppressor critically regulates TSC2 and mTOR, Proc. Natl. Acad. Sci. USA, 102, 8573, 10.1073/pnas.0503224102 · DOI · Paper page
  16. Kamangar, 2006, Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world, J. Clin. Oncol., 24, 2137, 10.1200/JCO.2005.05.2308 · DOI · Paper page
  17. Kim, 2010, Mouse models for breast cancer metastasis, Biochem. Biophys. Res. Commun., 394, 443, 10.1016/j.bbrc.2010.03.070 · DOI
  18. McGillicuddy, 2009, Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis, Cancer Cell, 16, 44, 10.1016/j.ccr.2009.05.009 · DOI · Paper page
  19. Miller, 2000, MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ, J. Natl. Cancer Inst., 92, 1185, 10.1093/jnci/92.14.1185a · DOI · Paper page
  20. Min, 2010, An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB, Nat. Med., 16, 286, 10.1038/nm.2100 · DOI · Paper page
  21. Mueller, 2000, Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients, Int. J. Cancer, 89, 384, 10.1002/1097-0215(20000720)89:4<384::AID-IJC11>3.0.CO;2-R · DOI
  22. Mueller, 2010, Reverse phase protein microarrays advance to use in clinical trials, Mol. Oncol., 4, 461, 10.1016/j.molonc.2010.09.003 · DOI
  23. Perou, 2000, Molecular portraits of human breast tumours, Nature, 406, 747, 10.1038/35021093 · DOI · Paper page
  24. Sivaraman, 1997, Hyperexpression of mitogen-activated protein kinase in human breast cancer, J. Clin. Invest., 99, 1478, 10.1172/JCI119309 · DOI · Paper page
  25. Sjöblom, 2006, The consensus coding sequences of human breast and colorectal cancers, Science, 314, 268, 10.1126/science.1133427 · DOI · Paper page
  26. Sørlie, 2001, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc. Natl. Acad. Sci. USA, 98, 10869, 10.1073/pnas.191367098 · DOI · Paper page
  27. Thomas, 2004, Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer, Clin. Cancer Res., 10, 8351, 10.1158/1078-0432.CCR-04-0130 · DOI
  28. von Lintig, 2000, Ras activation in human breast cancer, Breast Cancer Res. Treat., 62, 51, 10.1023/A:1006491619920 · DOI · Paper page
  29. Vousden, 2007, p53 in health and disease, Nat. Rev. Mol. Cell Biol., 8, 275, 10.1038/nrm2147 · DOI · Paper page

Cited by

See all 135

Metadata

Authors
McLaughlin, S. K., Olsen, S. N., Dake, B., De Raedt, T., Lim, E., Bronson, R. T., Beroukhim, R., Polyak, K., Brown, M., Kuperwasser, C., & Cichowski, K.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2013-09
Volume
24
Issue
3
Pages
365-378
ISSN
1535-6108 (ISSN-L)
OpenAlex
W2085659118
Cited by
135
References
17
FWCI
5.11
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor. https://app.cochat.ai/papers/10.1016/j.ccr.2013.08.004
The paper
McLaughlin, S. K., Olsen, S. N., Dake, B., De Raedt, T., Lim, E., Bronson, R. T., Beroukhim, R., Polyak, K., Brown, M., Kuperwasser, C., & Cichowski, K. (2013). The RasGAP Gene, RASAL2, Is a Tumor and Metastasis Suppressor. Cancer Cell. https://doi.org/10.1016/j.ccr.2013.08.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.